VIDEO: Port delivery system shows real-world efficacy, safety in neovascular AMD

ByArshad Khanani, MD, MA, FASRS

ByAnthony DeFino

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses efficacy and safety data for the port delivery system ahead of its reintroduction.

The data were derived from the SUMMIT study, which investigated real-world results in patients with neovascular age-related macular degeneration.

“The port delivery system (Susvimo, Genentech) is an innovative sustained-delivery platform,” he said. “In the real world, what we have seen is maintenance of visual acuity and [central subfield thickness] with a well-tolerated safety profile.”

Published by:

Sources/Disclosures

Collapse

Source:

Khanani A. Real world efficacy and safety of PDS in nAMD: The SUMMIT study. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Khanani reports consulting for and receiving research funding from Genentech.

Clinical Trials at the Summit meeting

Read more

VIDEO: Port delivery system shows real-world efficacy, safety in neovascular AMD

Related Content